Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 142

1.

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.

Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG.

Nat Genet. 2017 Nov 6. doi: 10.1038/ng.3990. [Epub ahead of print]

PMID:
29106415
2.

Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial.

Hegde JV, Shaverdian N, Daly ME, Felix C, Wong DL, Rosove MH, Garst JH, Wang PC, Veruttipong D, Rao S, Fragoso RC, Riess JW, Steinberg ML, Chen AM.

Cancer. 2017 Oct 17. doi: 10.1002/cncr.30954. [Epub ahead of print]

PMID:
29044458
3.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A.

J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.

PMID:
28447912
4.

Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer.

Gandara DR, Riess JW, Kelly K, Li T, Mack PC, Lara PN Jr.

Clin Lung Cancer. 2017 Jan;18(1):1-4. doi: 10.1016/j.cllc.2016.12.011. Epub 2016 Dec 24.

PMID:
28082049
5.

Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer.

Riess JW, Lara PN Jr, Gandara DR.

J Clin Oncol. 2016 Sep 6. pii: JCO690040. [Epub ahead of print] No abstract available.

6.

Multidisciplinary Care.

Daly ME, Riess JW.

Cancer Treat Res. 2016;170:285-300. doi: 10.1007/978-3-319-40389-2_13. Review.

PMID:
27535399
7.

New and emerging developments in extensive-stage small cell lung cancer therapeutics.

Parikh M, Riess J, Lara PN Jr.

Curr Opin Oncol. 2016 Mar;28(2):97-103. doi: 10.1097/CCO.0000000000000264. Review.

8.

Pruritus as a Paraneoplastic Symptom of Thymoma.

Padda SK, Shrager JB, Riess JW, Pagtama JY, Holmes Tisch AJ, Kwong BY, Liang Y, Schwartz EJ, Loo BW, Neal JW, Hardy R, Wakelee HA.

J Thorac Oncol. 2015 Nov;10(11):e110-2. doi: 10.1097/JTO.0000000000000623. No abstract available.

9.

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.

Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG.

Nat Med. 2015 Sep;21(9):1038-47. doi: 10.1038/nm.3930. Epub 2015 Aug 24.

10.

Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.

Das M, Padda SK, Frymoyer A, Zhou L, Riess JW, Neal JW, Wakelee HA.

Lung Cancer. 2015 Sep;89(3):280-6. doi: 10.1016/j.lungcan.2015.06.011. Epub 2015 Jun 22.

11.

Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform.

Gandara DR, Mack PC, Bult C, Li T, Lara PN Jr, Riess JW, Astrow SH, Gandour-Edwards R, Cooke DT, Yoneda KY, Moore EH, Pan CX, Burich RA, David EA, Keck JG, Airhart S, Goodwin N, de Vere White RW, Liu ET.

Clin Lung Cancer. 2015 May;16(3):165-72. doi: 10.1016/j.cllc.2015.03.001. Epub 2015 Mar 18.

12.

GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray.

Riess JW, West R, Dean M, Klimowicz AC, Neal JW, Hoang C, Wakelee HA.

Anticancer Res. 2015 Feb;35(2):669-76.

PMID:
25667444
13.

Pemetrexed in patients with thymic malignancies previously treated with chemotherapy.

Liang Y, Padda SK, Riess JW, West RB, Neal JW, Wakelee HA.

Lung Cancer. 2015 Jan;87(1):34-8. doi: 10.1016/j.lungcan.2014.11.006. Epub 2014 Nov 15.

PMID:
25443273
14.

Diffuse high intensity PD-L1 staining in thymic epithelial tumors.

Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, West RB, Wakelee HA.

J Thorac Oncol. 2015 Mar;10(3):500-8. doi: 10.1097/JTO.0000000000000429.

15.

Selected physicochemical aspects of poly- and perfluoroalkylated substances relevant to performance, environment and sustainability-part one.

Krafft MP, Riess JG.

Chemosphere. 2015 Jun;129:4-19. doi: 10.1016/j.chemosphere.2014.08.039. Epub 2014 Sep 20. Review.

PMID:
25245564
16.

Left behind? Drug discovery in extensive-stage small-cell lung cancer.

Riess JW, Lara PN Jr.

Clin Lung Cancer. 2014 Mar;15(2):93-5. doi: 10.1016/j.cllc.2013.12.010. Epub 2014 Jan 3.

17.

Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.

Riess JW, Nagpal S, Iv M, Zeineh M, Gubens MA, Ramchandran K, Neal JW, Wakelee HA.

Clin Lung Cancer. 2014 May;15(3):202-6. doi: 10.1016/j.cllc.2013.12.009. Epub 2014 Jan 1.

PMID:
24524822
18.

Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients.

Riess JW, Bhattacharya N, Blenman KR, Neal JW, Hwang G, Pultar P, San-Pedro Salcedo M, Engleman E, Lee PP, Malik R, Wakelee HA.

Immunopharmacol Immunotoxicol. 2014 Apr;36(2):182-6. doi: 10.3109/08923973.2013.864671. Epub 2014 Feb 5.

PMID:
24494587
19.

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.

Chen H, Modiano MR, Neal JW, Brahmer JR, Rigas JR, Jotte RM, Leighl NB, Riess JW, Kuo CJ, Liu L, Gao B, Dicioccio AT, Adjei AA, Wakelee HA.

Br J Cancer. 2014 Feb 4;110(3):602-8. doi: 10.1038/bjc.2013.735. Epub 2013 Nov 28.

20.

Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications.

Gandara DR, Li T, Lara PN, Kelly K, Riess JW, Redman MW, Mack PC.

Clin Lung Cancer. 2014 Jan;15(1):1-6. doi: 10.1016/j.cllc.2013.10.001. Epub 2013 Oct 12.

Supplemental Content

Support Center